Compare Shopify Inc. (SHOP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shopify Inc. vs 10X Genomics Inc — how do they compare? Shopify Inc. trades at $165.78 (market cap $211.73B), while 10X Genomics Inc trades at $78.75 (market cap $10.07B). The key difference: Shopify Inc. is far larger — about 21× 10X Genomics Inc's market cap, and Shopify Inc. is more actively traded (7,146,651 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold Shopify Inc. for 78 Days and 10X Genomics Inc for 92 Days on average.
| SHOP | TXG | |
|---|---|---|
Market Cap | $211.73B | $10.07B |
Volume | 7,146,651 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $179.01 | $97.74 |
52-Week Low | $95.40 | $11.48 |
Typical Hold Time | 78 Days | 92 Days |
Enterprise Value | $206.96B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shopify (SHOP) trades at $165.94, up 0.88% today, showing strong momentum near analyst consensus targets. The stock maintains a bullish technical outlook with solid fundamental growth - revenue increased from $5.6B in 2022 to $11.6B in 2025 while achieving profitability. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. The company continues to innovate with AI-powered commerce tools and expanding merchant solutions.
Shopify presents growth potential through e-commerce leadership and AI integration, though elevated valuation metrics (P/E 112, P/S 16) warrant caution. Key risks include competitive pressures from Amazon and valuation sensitivity to growth sustainability. Analyst consensus remains bullish with 67% buy ratings and $168.63 price target, suggesting modest upside from current levels.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
